Form 4: Director Stanley Frankel Exercises Precision Bio RSU Grant

Precision BioSciences director Stanley Frankel acquired 21,000 shares of common stock following the vesting of restricted stock units.

Summary

• Director Stanley Frankel acquired 21,000 shares of Precision BioSciences (DTIL) common stock on May 20, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs) granted on June 3, 2025.
• Following this transaction, the reporting person holds a total of 40,478 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard equity compensation vesting rather than a discretionary market purchase or sale.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.

Negatives

• None identified; this is a routine equity compensation vesting event.

Risks

• None identified; this is a standard regulatory disclosure of equity compensation.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine RSU vesting for board members is standard practice in the biotechnology sector to ensure long-term alignment between directors and corporate performance.

Comparison to Industry Standards

• The transaction follows standard industry practices for director compensation in clinical-stage biotech firms.
• The vesting schedule is consistent with typical equity incentive plans for public companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine issuance of equity under an existing compensation plan.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

DTIL, Precision BioSciences, Insider Trading, Form 4, Equity Compensation, Biotech